| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
Anesthesiology Research Laboratories, Departments of Anesthesiology and Physiology, Cardiovascular Research Center, The Medical College of Wisconsin, VA Medical Center Research Service, and Department of Biomedical Engineering, Marquette University, Milwaukee, Wisconsin
Address correspondence and reprint requests to David Stone, MD, PhD, Anesthesiology, 8701 Watertown Plank Road, Medical College of Wisconsin, Milwaukee, WI 53226. Address e-mail to dfstone{at}mcw.edu.
Reactive oxygen species (ROS) are central to cardiac ischemic and reperfusion injury. They contribute to myocardial stunning, infarction and apoptosis, and possibly to the genesis of arrhythmias. Multiple laboratory studies and clinical trials have evaluated the use of scavengers of ROS to protect the heart from the effects of ischemia and reperfusion. Generally, studies in animal models have shown such effects. Clinical trials have also shown protective effects of scavengers, but whether this protection confers meaningful clinical benefits is uncertain. Several IV anesthetic drugs act as ROS scavengers. In contrast, volatile anesthetics have recently been demonstrated to generate ROS in the heart, most likely because of inhibitory effects on cardiac mitochondria. ROS are involved in the signaling cascade for cardioprotection induced by brief exposure to a volatile anesthetic (termed "anesthetic preconditioning"). ROS, therefore, although injurious in large quantities, can have a paradoxical protective effect within the heart. In this review we provide background information on ROS formation and elimination relevant to anesthetic and adjuvant drugs with particular reference to the heart. The sources of ROS, the means by which they induce cardiac injury or activate protective signaling pathways, the results of clinical studies evaluating ROS scavengers, and the effects of anesthetic drugs on ROS are each discussed.
This article has been cited by other articles:
|
|
 |
|
  S. L. Shafer and V. Nekhendzy Anesthesia Matters: Statistical Anomaly or New Paradigm? Anesth. Analg., January 1, 2008; 106(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ballard-Croft, A. C. Locklar, B. J. Keith, R. M. Mentzer Jr, and R. D. Lasley Oxidative stress and adenosine A1 receptor activation differentially modulate subcellular cardiomyocyte MAPKs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H263 - H271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lessa and E. Tibirica Pharmacologic Evidence for the Involvement of Central and Peripheral Opioid Receptors in the Cardioprotective Effects of Fentanyl Anesth. Analg., October 1, 2006; 103(4): 815 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Bouwman, F. N. G. van't Hof, W. de Ruijter, B. J. van Beek-Harmsen, R. J. P. Musters, J. J. de Lange, and C. Boer The mechanism of sevoflurane-induced cardioprotection is independent of the applied ischaemic stimulus in rat trabeculae Br. J. Anaesth., September 1, 2006; 97(3): 307 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Zima and L. A. Blatter Redox regulation of cardiac calcium channels and transporters Cardiovasc Res, July 15, 2006; 71(2): 310 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Bovill Intravenous Anesthesia for the Patient with Left Ventricular Dysfunction Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2006; 10(1): 43 - 48. [Abstract] [PDF]
|
|
|
